Richter Bernd, Neises Gudrun, Clar Christine
Department of Metabolic Disorders and Nutrition, Heinrich-Heine University, Moorenstrasse 5, D-40225, Düsseldorf, Germany.
Endocrinol Metab Clin North Am. 2002 Sep;31(3):751-78. doi: 10.1016/s0889-8529(02)00008-7.
This systematic review highlights the uncertainty about the safety and efficacy of glucocorticoid withdrawal in many chronic diseases, elucidating the need for further research in this area. The problem of glucocorticoid withdrawal seems to be good example for wide variation in physicians' approaches to weaning patients off glucocorticoids. This practice variation appears justified, given the well known extraordinary array of individual reactions to systemic glucocorticoid therapy [44], the obligation to individualize treatment, and scientific uncertainty. Moreover, only sparse information concerning health-related quality of life, well-being and symptoms, and socioeconomic sequelae after glucocorticoid withdrawal is available from published randomized trials. In conclusion, clinicians and patients need many more--and in a number of conditions, initial--high quality studies to assess the safety and efficacy of systemic glucocorticoid withdrawal schedules in chronic diseases.
本系统评价凸显了许多慢性疾病中糖皮质激素撤药的安全性和有效性存在的不确定性,阐明了该领域进一步研究的必要性。糖皮质激素撤药问题似乎是医生在让患者停用糖皮质激素方法上存在广泛差异的一个典型例子。鉴于全身性糖皮质激素治疗存在众所周知的一系列不同个体反应、个体化治疗的必要性以及科学上的不确定性,这种实践差异似乎是合理的。此外,已发表的随机试验中仅有关于糖皮质激素撤药后健康相关生活质量、幸福感和症状以及社会经济后遗症的稀少信息。总之,临床医生和患者需要更多高质量研究,而且在许多情况下需要开展初始高质量研究,以评估慢性疾病中全身性糖皮质激素撤药方案的安全性和有效性。